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Abstract
Objectives: To study the association of the American Society of Anesthesiologists (ASA) physical status
score with long-term outcome in endometrial cancer.
Methods: Overall, disease-specific and non-cancer related survival were estimated using simple and
multivariable Cox regression analyses and the Kaplan-Meier method.
Results: A total of 1166 patients were included in the study. Median follow-up time was 76 months (range
1-136). All-cause and non-cancer related mortality were increased in patients whose ASA physical status
score was III (hazard ratios 2.5 and 8.0, respectively) or IV (hazard ratios 5.7 and 25, respectively), and
cancer-related mortality was increased in patients whose score was IV (hazard ratio 2.7). Kaplan-Meier
analyses demonstrated a worse overall, disease-specific and non-cancer related survival for patients
whose score was ≥III (P < 0.0001 for all). Disease-specific survival was also separately analyzed for
patients with stage I and stage II-IV cancer. Compared with patients whose score was ≤II, the survival
was worse for patients whose score was ≥III in both subgroups of stages (P = 0.003 and P = 0.017 for
stage I and stages II-IV, respectively). ASA physical status score remained an independent predictor of
all-cause mortality (hazard ratio 2.2 for scores ≥III), cancer-related mortality (hazard ratios 1.7 and 2.2
for scores ≥III and IV, respectively) and non-cancer related mortality (hazard ratio 3.1 for scores ≥III)
after adjustment for prognostically relevant clinicopathologic and blood-based covariates. ASA physical
status score also remained an independent predictor of cancer-related mortality after exclusion of patients
who were at risk for nodal involvement based on features of the primary tumor but did not undergo
lymphadenectomy, and patients with an advanced disease who received suboptimal chemotherapy
(hazard ratios 1.6 and 2.5 for scores ≥III and IV, respectively).
Conclusions: ASA physical status score independently predicts overall survival, disease-specific survival
and non-cancer related survival in endometrial cancer.
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Introduction
Endometrial cancer is the sixth most common cancer in women worldwide, with highest rates in North
America and Eastern and Northern Europe [1]. It is diagnosed predominantly in elderly women, the
median age being 62 years at diagnosis [2]. Compared with the general population, women with
endometrial cancer have an increased prevalence of comorbid conditions, most importantly obesity and
diabetes [3].
The American Society of Anesthesiologists (ASA) physical status classification system
was developed in 1941 to offer clinicians a simple categorization of a patient´s physiological status that
can be helpful in predicting operative risk [4]. The time frame around the perioperative period that the
ASA physical status classification system encompasses has not been defined. The latest version of the
classification system was approved in 2014 [5]. This update included examples of patient characteristics
that fit into each ASA physical status score, scaled from I to VI (Supplemental Table 1).
Although the ASA physical status classification system is mainly used for prediction of
perioperative morbidity and mortality, there is some evidence that it may also predict long-term outcome
of cancer patients. In those undergoing radical surgery for urinary bladder cancer or upper tract urothelial
carcinoma, ASA physical status score independently predicts overall mortality [6-8]. Here, we wanted to
test a hypothesis that high ASA physical status score is associated with an unfavorable long-term outcome
in women with endometrial cancer.
Materials and Methods
Patients who underwent primary surgical treatment for endometrial cancer at the Department of Obstetrics
and Gynecology, Helsinki University Hospital, between January 1, 2007 and December 31, 2013 were
included in this study. The study was approved by the Institutional Review Board (journal number
135/13/03/03/2013) and the National Supervisory Authority for Welfare and Health (journal number
753/06.01.03.01/2016). Clinicopathologic data were abstracted from institutional medical and pathology
records. ASA physical status scores were abstracted from anesthesia records and then revised to comply
with the 2014 update of the ASA physical status classification system [5]. Specifically, current smokers
and subjects with obesity (30 kg/m2 < body mass index < 40 kg/m2) or well-controlled diabetes were
classified as ASA physical status score II patients, whereas those with severe obesity (body mass index
≥40 kg/m2) were classified as ASA physical status score III patients. Body mass index was unknown for
one patient whose ASA physical status score was IV. Stage was determined according to the International
Federation of Gynecology and Obstetrics guidelines revised in 2009 [9].
Follow-up data were last updated in January-March 2018, together with clinicopathologic
data where appropriate. All survival times were calculated from the date of surgery to death to obviate
the measurement error due to imprecision in estimating the day of diagnosis. Cause of death was mainly
based on medical records. Missing data were complemented from death certificates derived from
Statistics Finland.
The standard surgical treatment was total hysterectomy with bilateral salpingo-
oophorectomy. Lymphadenectomy was performed in selected patients. Adjuvant therapy was tailored
according to stage and histologic findings at surgery. Patients with early stage endometrioid cancer with
high risk features generally received either vaginal brachytherapy or whole pelvic radiotherapy, and
patients with nonendometrioid or advanced (stage III-IV) endometrioid cancer received multimodality
treatment with chemotherapy and radiation.
Variables of the last pretreatment complete blood count were analyzed by photometric
measurement (hemoglobin) and electrical impedance technology and flow cytometry (cells). Anemia was
defined as blood hemoglobin concentration <117 g/L, leukocytosis as a leukocyte count >8.2 x 109/L, and
thrombocytosis as a platelet count >360 x 109/L. These values represent the reference intervals for Finnish
adult females [10]. Blood count variables were not available for one patient. Pretreatment CA125
concentration was quantitated with a chemiluminescent microparticle immunoassay on the Abbott
Architect 2000i Analyzer (Abbott Diagnostics, Abbott Park, Illinois, USA). The concentration was
considered increased when >35 U/mL [11]. The value of CA125 was not available for 121 patients.
Pearson χ2 or Fisher exact test was used for comparisons of categorical variables. Survivals
were estimated using simple and multivariable Cox regression analyses and the Kaplan-Meier method.
Differences between groups were compared using the log rank test. Statistical significance was set at P <
0.05. Data were analyzed using the Statistical Package for the Social Sciences version 24 software (IBM
Corp., Armonk, New York, USA).
Results
A total of 1166 patients were included in the study (Table 1). Of these, the ASA physical status score was
I in 49 (4.2%), II in 478 (41.0%), III in 548 (47.0%), and IV in 91 (7.8%). None of the patients had a
score of V or VI.
Of the patients who had stage IA-IIIC2 endometrioid cancer and were at low-intermediate
to high risk for lymph node involvement according to the Milwaukee criteria of primary tumors [12],
69.2% (323/467) underwent pelvic or pelvic-aortic lymphadenectomy. Of those at low risk [12], 57.9%
(287/496) underwent lymphadenectomy (due to missing data, denominators do not add up to 1027, which
was the total number of stage IA-IIIC2 endometrioid cancers). Of the patients with stage IA-IIIC2
nonendometrioid cancer, 79.4% (77/97) underwent lymphadenectomy. Two patients with stage IVB
cancer underwent surgical exploration without hysterectomy.
Of the 203 patients who were treated with at least one cycle of combination chemotherapy,
164 (80.8%) received paclitaxel and carboplatin and 36 (17.7%) received epirubicin and carboplatin.
Paclitaxel was changed to docetaxel in 17 patients because of paclitaxel toxicity, and two (1.0%) patients
received docetaxel as a taxane drug in all treatment cycles. One patient (0.5%) received first epirubicin
and then paclitaxel in combination with carboplatin. Forty-four patients received carboplatin
monotherapy.
Seven patients died within 30 days after surgery, which gives a rate of 0.6% for
perioperative mortality. Of these seven patients, the ASA physical status score was II in one, III in three,
and IV in three. Six patients had stage IVB cancer. One patient whose ASA physical status score was IV
had stage IA cancer, and she was the only patient whose perioperative death was not caused by
endometrial cancer. Of the 304 (26.1%) patients who died during follow-up, 176 (15.1%) died from
endometrial cancer and 128 (11.0%) from other causes. Median follow-up time was 76 months (range 1-
136).
Simple Cox regression analyses were performed with ASA physical status score I as
reference (Table 2). All-cause mortality and non-cancer related mortality were increased in patients whose
score was III or IV, and cancer-related mortality was increased in patients whose score was IV. Risk of
death was not altered in patients whose score was II.
Covariates for the multivariable survival analyses were selected based on unadjusted
analyses of potential risk factors (Table 2). In addition to the ASA physical status score, the following
covariates showed significant associations with all-cause mortality and were included in the multivariable
analysis: age, diabetes, histology, stage, blood hemoglobin concentration and leukocyte count, serum
CA125 concentration, and type of adjuvant therapy. In the multivariable analysis, ASA physical status
score ≥III, age ≥60, endometrioid grade 3 and nonendometrioid histology, stage II-IV, anemia and
elevated serum CA125 increased all-cause mortality (Table 3). Whole pelvic radiotherapy, chemotherapy
and multimodality treatment decreased all-cause mortality (Table 3).
Diabetes was not significantly associated with cancer-related mortality in unadjusted
analyses. It was excluded from the multivariable analysis of cancer-related mortality, which demonstrated
ASA physical status score, age, histology, stage, serum CA125 and type of adjuvant therapy as
independent prognosticators (Table 3). We also re-ran the same model with the cut-off for ASA physical
status score set at III instead of IV. ASA physical status score remained an independent predictor of
cancer-related mortality (hazard ratio 1.7, 95% confidence interval 1.2-2.4; P = 0.002).
Of the patients with stage I-IIIC2 endometrioid cancer who did not satisfy the low-risk
Milwaukee criteria for lymph node involvement [12], the lymphadenectomy rate was 84.3% (167/198) in
those whose ASA physical status score was I or II, as opposed to 58.0% (156/269) in those whose score
was III or IV (P < 0.0001). In patients with stage I-IIIC2 nonendometrioid cancer, the lymphadenectomy
rate was 87.9% (29/33) in those whose ASA physical status score I or II, and 75.0% (48/64) in those
whose score was higher (P = 0.188). In the subgroup of patients with stage III-IV cancer, 78.5% (62/79)
of those with an ASA physical status score of I or II and 55.2% (64/116) of those with a score of III or
IV received chemotherapy with a curative intent, defined as a minimum of six cycles of combination
chemotherapy (P = 0.001). When patients who were allowed to forgo lymphadenectomy despite not
satisfying the low-risk Milwaukee criteria [12] and patients with stage III-IV cancer who received
suboptimal chemotherapy were excluded from the multivariable analysis of cancer-related mortality,
ASA physical status score remained an independent predictor of poor outcome at a cut-off of III (hazard
ratio 1.6, 95% confidence interval 1.1-2.3; P = 0.011) and IV (hazard ratio 2.5, 95% confidence interval
1.4-4.4; P = 0.001).
ASA physical status score, age, diabetes, histology, anemia and CA125 were associated
with non-cancer related mortality in unadjusted analyses (Table 2). ASA physical status score and age
were the strongest predictors of non-cancer related mortality in multivariable analysis (Table 3).
Of the 217 diabetic patients, 193 (88.9%) had an ASA physical status score of III or IV
due to poor control of diabetes or additional comorbidities. Because of the obvious overlap between ASA
physical status score and diabetes as covariates in multivariable analyses of all-cause mortality and non-
cancer related mortality (Table 3), these analyses were also performed after excluding either ASA
physical status score or diabetes. Hazard ratios remained essentially unaltered for the remaining
covariates; however, after exclusion of ASA physical status score, diabetes showed a significant effect
on both all-cause mortality (hazard ratio 1.4, 95% confidence interval 1.1-1.9; P = 0.018) and non-cancer
related mortality (hazard ratio 2.1, 95% confidence interval 1.4-3.1; P = 0.001).
Based on multivariable analyses, ASA physical status score III was chosen as the cut-off
for Kaplan-Meier survival analyses. These plots demonstrated a worse overall survival, disease-specific
survival and non-cancer related survival for patients whose ASA physical status score was ≥III (Figure
1A-C). Disease-specific survival was also separately analyzed for patients with stage I and stage II-IV
cancer. Compared with patients whose ASA physical status score was ≤II, the survival was worse for
patients whose score was ≥III in both subgroups of stages (Figure 2A-B).
Discussion
Prognostic factors for endometrial cancer have been extensively investigated, with an intention to provide
tools for individualized treatment, tailored follow-up, and patient counseling. Stage and features of the
primary tumor, such as histologic subtype, grade, depth of myometrial invasion and lymphovascular space
invasion, are among the most commonly used prognosticators in clinical practice [13]. Many tissue
biomarkers, e.g. L1CAM [14,15] and estrogen and progesterone receptor status [16], have been proposed
as molecular determinants of patient outcome. Of the blood-based assays, CA125 [17] and HE4 [18] have
been suggested to serve as prognostic biomarkers in endometrial cancer. Moreover, abnormalities in the
preoperative complete blood count, i.e. anemia, leukocytosis and thrombocytosis, appear to be poor
prognostic findings [19]. However, none of the tissue biomarkers or blood-based tests are widely used in
gynecologic oncology practices. The Cancer Genome Atlas molecular classification, which divides
endometrial cancers into four distinct categories [20], improves assessment of prognosis compared with
conventional risk factors alone and holds promise in reducing overtreatment and undertreatment [21,22].
Of the clinical patient characteristics, high age has been found to be associated with poor
outcome in endometrial cancer [23,24]. Specifically, age ≥60 years is an independent predictor of
locoregional relapses and disease-related death in stage I endometrial cancer [25], and was chosen as the
cut-off for high age in the current study. Findings on the prognostic significance of obesity and diabetes
are less consistent, but prevailing data suggest that they are associated with poor overall survival [3,26].
Data presented herein provide a novel prognostic instrument in women with endometrial
cancer, as the ASA physical status score was found to be associated with poor long-term outcome. It
could be argued that surgical understaging and/or weaker tolerance may have lead to a more frequent use
of suboptimal adjuvant therapy in patients with a high ASA physical status score, and, consequently,
worse outcome. The evidence for improved survival by adjuvant therapy in endometrial cancer is best for
chemotherapy in advanced cases [13]. ASA physical status score remained an independent predictor of
cancer-related mortality even after exclusion of patients who were at risk for nodal metastasis as per the
Milwaukee criteria [12] but did not undergo lymphadenectomy, and patients with an advanced disease
who received suboptimal chemotherapy. ASA physical status score also remained an independent
predictor of cancer-related mortality after adjusting for the type of adjuvant therapy. Thus, differences in
surgical treatment or adjuvant therapies unlikely explain our findings.
Hazard ratios were quite similar for all significant risk factors in the multivariable analyses
of all-cause mortality and non-cancer related mortality. By contrast, compared with ASA physical status
score, the hazard ratio was somewhat higher for stage in the multivariable analysis of cancer-related
mortality. It should be remembered, however, that the hazard ratio for ASA physical status score did not
differ from that for age, a risk factor that was strong enough to be included in two prognostic nomograms
for endometrial cancer [27,28]. The ASA physical status classification system may similarly deserve
attention in the prognostication of endometrial cancer. It is noteworthy that this classification system
predicted disease-specific survival also in the subgroup of stage I cancers that sometimes tend to leave
clinicians with uncertainty regarding the true potential for the disease to recur.
Despite the fact that the ASA physical status classification system was originally
developed to predict operative risk [4], it seems unlikely that a high perioperative mortality can explain
the worse outcome of patients with high ASA physical status scores during the whole follow-up time. Six
of the seven patients who died within 30 days after surgery had an ASA physical status score of III or IV;
all of them succumbed to stage IVB endometrial cancer, which generally has a very poor prognosis.
We assume that the effect of obesity on the poor outcome of patients with a high ASA
physical status score was not considerable because body mass index was not associated with increased
all-cause, cancer-related or non-cancer related mortality in univariable analyses. Similarly, based on
univariable analysis, diabetes was not associated with cancer-related mortality. The effect of diabetes may
be more important on deaths unrelated to endometrial cancer because it increased all-cause mortality and
non-cancer related mortality in multivariable analyses after exclusion of ASA physical status score as a
covariate.
Our study is strengthened by the large sample size and prospectively maintained database
with long follow-up time. One of the end-points was disease-specific survival, which is the ideal outcome
of interest after a cancer diagnosis. Detailed clinicopathologic data allowed us to control for the most
common confounding factors. Presumably, this mitigated the shortcomings associated with the
retrospective design of the study.
Although the external validity of the current findings will need to be verified in other
patient samples, it is reassuring that the stage distribution and proportion of nonendometrioid cancers
were comparable to findings in the Gynecologic Oncology Group 210 surgical pathological staging study
of 5866 patients, with the vast majority being local endometrioid cancers [29]. Further, the proportion of
women who had at most a mild systemic disease, based on their ASA physical status score of I or II, was
very similar to a population-based analysis of 5408 women who underwent hysterectomy for endometrial
cancer across the United States (45% and 43% in our study and in the population-based analysis,
respectively) [30].
The biological mechanisms by which the ASA physical status score might have an impact
on endometrial cancer-related mortality remain to be elucidated. However, the current findings can be
considered to be consistent with an earlier report in which frailty, i.e. state of low functional reserve seen
particularly in old subjects, predicted shortened overall survival and disease-free survival in women with
endometrial cancer [31]. It could be speculated that the partly subjective nature of the ASA physical status
classification system allows frailty and other difficultly measurable clinical findings to be translated into
a worse classification [32]. Clearly, more knowledge is needed to better understand the interaction
between physical fitness and cancer survival.
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Figure legends
Figure 1. Kaplan-Meier survival analyses concerning the American Society of Anesthesiologists (ASA)
physical status classification system in patients with endometrial cancer.
Figure 2. Kaplan-Meier disease-specific survival analyses concerning the American Society of
Anesthesiologists (ASA) physical status classification system in patients with stage I (A) and stage II-IV
(B) endometrial cancer.
Table 1. Clinicopathologic data (n = 1166).
Clinicopathologic feature Result
Age (years) [median (interquartile range)] 68 (60-75)
Body mass index (kg/m2) [median (interquartile range)]* 27.5 (24.0-32.4)
Diabetes (number of cases, percent)† 217 (18.6%)
Current smokers (number of cases, percent) 125 (10.7%)
Minimally invasive hysterectomy (number of cases, percent)‡ 912 (78.2%)
Pelvic lymphadenectomy (number of cases, percent) 580 (49.7%)
Pelvic-aortic lymphadenectomy (number of cases, percent) 175 (15.0%)
Histology (number of cases, percent)
Endometrioid carcinoma
Clear cell carcinoma
Serous carcinoma
Carcinosarcoma
Undifferentiated carcinoma
Neuroendocrine carcinoma
1041 (89.3%)
43 (3.7%)
43 (3.7%)
20 (1.7%)
18 (1.5%)
1 (0.1%)
Grade (number of cases, percent) (For endometrioid only, n = 1041)
1
2
3
643 (55.1%)
265 (22.7%)
133 (11.4%)
Stage (number of cases, percent)
IA
IB
II
IIIA
IIIB
IIIC1
IIIC2
IVA
IVB
681 (58.4%)
224 (19.2%)
66 (5.7%)
54 (4.6%)
11 (0.9%)
55 (4.7%)
33 (2.8%)
0 (0%)
42 (3.6%)
Adjuvant therapy (number of cases, percent)
Vaginal brachytherapy
Pelvic radiotherapy
Chemotherapy
Chemotherapy and vaginal brachytherapy
Chemotherapy and pelvic radiotherapy
503 (43.1%)
149 (12.8%)
47 (4.0%)
67 (5.7%)
133 (11.4%)
*Number of cases 1165 (body mass index missing for one patient)
†Type 2 diabetes, n = 215; type 1 diabetes, n = 2
‡Laparoscopic, n = 829 (including 51 conversions); robotic, n = 72; vaginal, n = 11
Table 2. Simple Cox regression analyses of all-cause mortality, cancer-related mortality and non-cancer related
mortality (n = 1166).
All-cause mortality
(n deaths = 304)
Cancer-related mortality
(n deaths = 176)
Non-cancer related
mortality (n deaths = 128)
HR (95% CI) P HR (95% CI) P HR (95% CI) P
ASA physical status score
I (n = 49)
II (n = 478)
III (n =548)
IV (n = 91)
1
1.1 (0.51-2.4)
2.5 (1.2-5.3)
5.7 (2.6-13)
0.785
0.017
<0.0001
1
0.88 (0.38-2.1)
1.6 (0.70-3.6)
2.7 (1.1-6.6)
0.768
0.268
0.032
1
2.5 (0.34-18)
8.0 (1.1-58)
25 (3.4-180)
0.371
0.039
0.001
Age ≥60 years (n = 905) 2.8 (1.9-4.0) <0.0001 2.0 (1.3-3.0) 0.002 5.1 (2.5-10) <0.0001
Body mass index
(continuous) (n = 430)*
0.99 (0.97-1.0) 0.180 0.99 (0.97-1.0) 0.509 0.98 (0.95-1.0) 0.197
Diabetes (n = 217) 1.7 (1.3-2.2) <0.0001 1.3 (0.91-1.9) 0.153 2.3 (1.6-3.3) <0.0001
Histology
Endometrioid
grade 1-2 (n = 908)
Endometrioid
grade 3 (n = 133)
Nonendometrioid (n = 125)
1
2.8 (2.1-3.8)
4.3 (3.3-5.7)
<0.0001
<0.0001
1
4.4 (3.0-6.4)
6.9 (4.9-9.8)
<0.0001
<0.0001
1
1.4 (0.82-2.4)
2.0 (1.2-3.3)
0.213
0.013
Stage II-IV (n = 260) 3.4 (2.7-4.3) <0.0001 7.4 (5.4-10) <0.0001 0.83 (0.50-1.4) 0.453
Anemia (n = 132)* 2.6 (1.9-3.4) <0.0001 2.4 (1.6-3.4) <0.0001 2.9 (1.9-4.4) <0.0001
Leukocytosis (n = 280)* 1.5 (1.2-1.9) 0.001 1.8 (1.3-2.4) <0.0001 1.2 (0.80-1.8) 0.393
Thrombocytosis (n = 92)* 1.2 (0.80-1.8) 0.390 1.5 (0.92-2.4) 0.102 0.81 (0.39-1.6) 0.553
Elevated serum CA125
(n = 293)†
2.5 (2.0-3.1) <0.0001 3.1 (2.3-4.2) <0.0001 1.8 (1.2-2.6) 0.003
Adjuvant therapy
None or vaginal 1 1 1
brachytherapy (n = 770)
Pelvic radiotherapy
(n =149)
Chemotherapy (n = 114)
Chemotherapy and pelvic
radiotherapy (n = 133)
1.5 (1.1-2.1)
3.2 (2.3-4.3)
2.5 (1.9-3.5)
0.020
<0.0001
<0.0001
2.7 (1.7-4.3)
6.0 (4.0-9.0)
5.5 (3.7-8.0)
<0.0001
<0.0001
<0.0001
0.74 (0.40-1.3)
1.3 (0.73-2.3)
0.63 (0.31-1.3)
0.315
0.361
0.212
*Data missing for one patient.
†Data missing for 121 patients.
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Table 3. Multivariable Cox regression analyses of all-cause mortality, cancer-related mortality and non-
cancer related mortality. Patients with available data for all of the selected covariates were included in the
models (n = 1044).
All-cause mortality
(n deaths = 277)
Cancer-related mortality
(n deaths = 164)
Non-cancer related
mortality (n deaths = 113)
HR (95% CI) P HR (95% CI) P HR (95% CI) P
ASA physical status
score III-IV
2.2 (1.7-2.9) <0.0001 3.1 (1.9-5.1) <0.0001
ASA physical status
score IV
2.2 (1.4-3.5) 0.001
Age ≥60 years 2.1 (1.4-3.0) <0.0001 1.8 (1.1-2.8) 0.015 3.6 (1.7-7.4) 0.001
Diabetes 1.1 (0.82-1.5) 0.551 ‒ 1.5 (0.99-2.3) 0.055
Histology
Endometrioid
grade 1-2
Endometrioid
1
2.9 (2.0-4.1) <0.0001
1
3.4 (2.2-5.4) <0.0001
1
1.2 (0.66-2.2) 0.544
grade 3
Nonendometrioid 2.9 (2.0-4.2) <0.0001 3.5 (2.2-5.5) <0.0001 1.2 (0.64-2.1) 0.641
Stage II-IV 3.5 (2.4-5.3) <0.0001 6.3 (3.9-10) <0.0001 ‒
Anemia 1.7 (1.2-2.3) 0.001 1.4 (0.94-2.1) 0.095 2.0 (1.2-3.2) 0.008
Leukocytosis 1.1 (0.84-1.4) 0.469 1.2 (0.87-1.7) 0.249 ‒
Elevated serum CA125 1.8 (1.4-2.3) <0.0001 1.6 (1.1-2.2) 0.006 1.8 (1.2-2.6) 0.005
Adjuvant therapy
None or
vaginal brachytherapy
Pelvic radiotherapy
Chemotherapy
Chemotherapy and
pelvic radiotherapy
1
0.54 (0.34-0.84)
0.46 (0.27-0.78)
0.37 (0.22-0.63)
0.007
0.004
<0.0001
1
0.63 (0.36-1.1)
0.54 (0.29-1.0)
0.48 (0.26-0.89)
0.116
0.050
0.020
‒
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